Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda to Split Part of Research Biz Into New Subsidiary
Takeda Pharmaceutical said on May 15 that it has formed a wholly owned subsidiary that would take over part of the company’s research operations in Japan as part of its global R&D transformation to boost its focus on priority therapeutic…
To read the full story
Related Article
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
BUSINESS
- JCR’s Izcargo Reels in Conditional Approval in Kuwait
October 15, 2026
- Nxera Licenses Quviviq to Taiwan’s Synmosa in 8 APAC Markets
October 15, 2026
- Rhythm’s Imcivree Debuts in Japan for Acquired Hypothalamic Obesity
October 15, 2026
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…